0001640455-21-000016.txt : 20210122
0001640455-21-000016.hdr.sgml : 20210122
20210122183557
ACCESSION NUMBER: 0001640455-21-000016
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210120
FILED AS OF DATE: 20210122
DATE AS OF CHANGE: 20210122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Drapkin Kimberlee C
CENTRAL INDEX KEY: 0001340881
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 21547394
MAIL ADDRESS:
STREET 1: PREDIX PHARMACEUTICALS HOLDINGS, INC.
STREET 2: 4 MAGUIRE ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wf-form4_161135854303039.xml
FORM 4
X0306
4
2021-01-20
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001340881
Drapkin Kimberlee C
C/O JOUNCE THERAPEUTICS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
0
1
0
0
CFO and Treasurer
Common Stock
2021-01-20
4
M
0
3016
0.48
A
58897
D
Common Stock
2021-01-20
4
M
0
6775
0.74
A
65672
D
Common Stock
2021-01-20
4
M
0
3710
2.36
A
69382
D
Common Stock
2021-01-20
4
S
0
16201
12.03
D
53181
D
Common Stock
2021-01-20
4
S
0
10000
10.03
D
43181
D
Common Stock
2021-01-21
4
M
0
3799
2.36
A
46980
D
Common Stock
2021-01-21
4
S
0
3799
12
D
43181
D
Stock Option (Right to Buy)
0.48
2021-01-20
4
M
0
3016
0
D
2024-01-27
Common Stock
3016.0
0
D
Stock Option (Right to Buy)
0.74
2021-01-20
4
M
0
6775
0
D
2025-01-12
Common Stock
6775.0
0
D
Stock Option (Right to Buy)
2.36
2021-01-20
4
M
0
3710
0
D
2025-08-25
Common Stock
3710.0
209804
D
Stock Option (Right to Buy)
2.36
2021-01-21
4
M
0
3799
0
D
2025-08-25
Common Stock
3799.0
206005
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions.
Represents the weighted average share price of an aggregate total of 16,201 shares sold in the price range of $12.00 to $12.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $10.00 to $10.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average share price of an aggregate total of 3,799 shares sold at $12.00 and $12.01 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The option shares vested and became exercisable in 12 monthly installments from October 9, 2013.
The option shares vested and became exercisable in 12 monthly installments from October 9, 2014.
25% of the option shares vested and became exercisable on August 26, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter.
/s/ Kimberlee C. Drapkin
2021-01-22